Vivo Capital’s Arvinas ARVN Stock Holding History

Vivo Capital’s Portfolio ARVN Stock Details ARVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-209,666	Closed	-$2.69M	–	50
2018 Q4	$2.69M	Sell	209,666 -90,334	-30%	-$1.43M	0.34%	34
2018 Q3	$5.06M	Buy	+300,000	New	+$4.94M	0.51%	33

Other funds holding ARVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital's ARVN Position: Q1 2019 in Review

Vivo Capital sold out of Arvinas (ARVN) in Q1 2019, closing a stake of 209,666 shares — an estimated $2.69M sold.

Vivo Capital first reported a position in ARVN in Q3 2018 and held it in 2 quarters. The position peaked at $5.06M in Q3 2018. 57 funds tracked by Wall St. Rank hold ARVN as of Q1 2019.

Vivo Capital reported no remaining Arvinas position as of Q1 2019 after selling out during the quarter.
Vivo Capital sold 209,666 Arvinas shares in Q1 2019, an estimated $2.69M.
Vivo Capital first reported a position in Arvinas in Q3 2018 and held it in 2 quarters.
Vivo Capital's Arvinas position peaked at $5.06M in Q3 2018.
57 funds tracked by Wall St. Rank held Arvinas as of Q1 2019.

Based on Vivo Capital's 13F filing for Q1 2019, filed 14 May 2019.